8-K: Gyre Therapeutics Reports Q1 2025 Financial Results: Net Income $3.7 Million, Reaffirms Full-Year Revenue Guidance

Gyre Therapeutics announces Q1 2025 financial results with a net income of $3.7 million and reaffirms its full-year revenue guidance of $118-$128 million.

Summary

• Gyre Therapeutics reported Q1 2025 revenue of $22.1 million, a decrease from $27.2 million in the same period last year, primarily due to lower sales of ETUARY.
• Net income for Q1 2025 was $3.7 million, compared to $9.9 million in Q1 2024.
• The company reaffirmed its full-year 2025 revenue guidance of $118 to $128 million.
• Gyre initiated commercialization of avatrombopag in China in March 2025 and remains on track to commercialize nintedanib in May 2025.
• The company completed data collection for the Phase 3 trial of Hydronidone in Chronic Hepatitis B (CHB)-associated liver fibrosis and expects to report topline results in Q2 2025.
• Gyre received IND approval from China's NMPA for pirfenidone to treat radiation-induced lung injury (RILI).
• As of March 31, 2025, Gyre held $51.3 million in cash, cash equivalents, and short and long-term deposits.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and net income decreased compared to the previous year, the company is reaffirming its full-year revenue guidance and has several upcoming product launches and clinical trial milestones. The decrease in revenue is attributed to a planned shift in marketing resources and weaker economic conditions, which are external factors.

Positives

• Gyre Therapeutics achieved a net income of $3.7 million in Q1 2025.
• The company is reaffirming its full-year revenue guidance of $118 to $128 million.
• Gyre received IND approval from China's NMPA for a new indication of pirfenidone to treat radiation-induced lung injury (RILI).
• The company initiated commercialization of avatrombopag in China in March 2025.
• Nintedanib is on track for commercialization in May 2025.
• Gyre has $51.3 million in cash, cash equivalents, and short and long-term deposits.

Negatives

• Q1 2025 revenue decreased to $22.1 million from $27.2 million in the same period last year.
• Net income decreased to $3.7 million from $9.9 million in the same period last year.
• ETUARY sales declined year-over-year due to relatively high sales in the first quarter of 2024 and increased competition.

Risks

• Weaker economic conditions in China and increased competition in the IPF treatment market contributed to the decline in ETUARY sales.
• The company's future performance is subject to risks and uncertainties, including the ability to execute on clinical development strategies and the timing of regulatory filings and approvals.
• The company's ability to raise additional capital is a risk factor.

Future Outlook

Gyre anticipates revenue growth over the remainder of the year, driven by the planned commercial launch of Nintedanib in May 2025 and the continued expansion of avatrombopag, reaffirming its full-year 2025 revenue guidance of $118 to $128 million.

Management Comments

• Han Ying, Ph.D., CEO of Gyre Therapeutics, stated that the quarter marked a meaningful step forward in expanding their market presence, particularly in the liver space.
• The CEO also noted that the successful launch of avatrombopag and their growing commercial footprint with hepatology and hematology specialists provide a strong foundation for future growth.
• Han Ying highlighted the NMPA approval to initiate a clinical trial of pirfenidone in radiation-induced lung injury, supporting their ability to enter the oncology supportive care space.

Industry Context

Gyre is expanding its presence in the pulmonary fibrosis and liver disease treatment markets, competing with established players. The company's entry into oncology supportive care with pirfenidone for radiation-induced lung injury represents a diversification strategy. The launch of avatrombopag and nintedanib aims to capture a larger share of the hepatology and pulmonology markets in China.

Comparison to Industry Standards

• ETUARY (pirfenidone) maintains a prominent market share in China for IPF treatment, with 2024 net sales of $105.8 million, indicating a strong position compared to other IPF drugs in the region.
• The development of F351 (Hydronidone) as a structural analogue of pirfenidone suggests a strategy to compete with existing anti-fibrotic drugs, potentially offering improved efficacy or safety profiles.
• The expansion into oncology supportive care with pirfenidone for RILI positions Gyre against companies developing treatments for cancer-related complications, such as supportive care drugs from companies like Helsinn Healthcare or Tesaro (now part of GSK).

Management Changes

Stakeholder Impact

• Shareholders: The financial results and future outlook will impact shareholder value.
• Employees: The company's performance and pipeline progress may affect employee morale and job security.
• Customers: The launch of new products like nintedanib and avatrombopag will provide additional treatment options for patients.
• Suppliers: The company's commercial activities will impact its relationships with suppliers.
• Creditors: The company's financial position will influence its ability to meet its obligations to creditors.

Next Steps

• Report topline results of the Phase 3 trial of Hydronidone in CHB-associated liver fibrosis in Q2 2025.
• Commercially launch nintedanib in May 2025.
• Initiate an adaptive Phase 2/3 trial of pirfenidone in radiation-induced lung injury in the second half of 2025.
• Begin a Phase 1 trial of F230 for the treatment of PAH in Q2 2025.
• Complete the Phase 2 clinical trial of F573 for ALF/ACLF by the end of 2026.
• Submit an IND application for F528 in COPD in 2026.

Key Dates

Keywords

Gyre Therapeutics, Financial Results, Q1 2025, Revenue Guidance, Hydronidone, Pirfenidone, Avatrombopag, Nintedanib, Liver Fibrosis, Lung Injury, Commercialization, Clinical Trials